Biotech stock Viking Therapeutics down 52% but has potential to soar by 233%

From Nasdaq: 2025-03-20 07:19:00

Viking Therapeutics (NASDAQ: VKTX) saw its stock soar last year after positive midstage clinical trial results, but has since dropped 52%. Despite this, analysts are bullish, with an average price target of $99.29, representing a 233% upside. The company’s leading candidate, VK2735, is a weight loss medicine, with recent developments indicating it won’t be acquired soon. Viking Therapeutics has promising assets in weight management and other areas, with plans for phase 3 studies for VK2735. Long-term investors may see potential in this mid-cap biotech company.

Experts are recommending a “Double Down” stock strategy for companies on the brink of success. Investing in companies like Nvidia, Apple, and Netflix when recommended in the past has yielded significant returns. Currently, there are new opportunities for investors to consider before they miss out. Consider taking advantage of this potentially lucrative second chance.



Read more at Nasdaq: 1 Biotech Stock Down 52% That Could Soar by 233%, According to Wall Street